Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ocunexus Therapeutics Inc. maintains a portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These matters are distributed across 2 distinct art units, reflecting technical diversity in the company's active patent applications. The involvement of 2 distinct art units suggests that the company's intellectual property spans different specialized sub-fields within the broader biotechnology sector.
The prosecution of these 2 pending office actions involves 2 distinct examiners, ensuring that the company's applications are being reviewed independently. The busiest examiner for the portfolio is ROBINSON, MIKHAIL O'DONNEL, who is currently managing 1 pending office action. This distribution means that the remaining pending action is assigned to another examiner, preventing a single official from controlling the entire active portfolio.
Practitioners should note that the presence of 2 pending office actions across 2 distinct examiners requires a coordinated approach to ensure consistency in claim language. Managing 2 pending office actions across 2 distinct art units allows the company to progress its intellectual property goals on multiple fronts simultaneously. Monitoring the 1 pending office action under ROBINSON, MIKHAIL O'DONNEL alongside the other active matter is essential for the Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642641 | COMPOSITIONS AND METHODS FOR RESCUING RETINAL AND CHOROIDAL STRUCTURE AND FUNCTION | ROBINSON, MIKHAIL O'DONNEL | 38d overdue |
| 17119776 | CHANNEL MODULATORS | CHERNYSHEV, OLGA N | 30d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17642641 | COMPOSITIONS AND METHODS FOR RESCUING RETINAL AND CHOROIDAL STRUCTURE AND FUNCTION | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Final Rejection | 38d overdue | Pending | Mar 11, 2022 |
| 17119776 | CHANNEL MODULATORS | CHERNYSHEV, OLGA N | 1675 | Other | Non-Final OA | 30d | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial